Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.581
Journals
Metabolites
Special Issues
Advances in Cardiometabolic Research
share announcement

Special Issue "Advances in Cardiometabolic Research"

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 1748

Special Issue Editors

Prof. Dr. Antonio Cittadini

E-Mail Website
Guest Editor
Department of Translational Medical Sciences, “Federico II” University Hospital and School of Medicine, Naples, Italy
Interests: cardiovascular endocrinology; heart failure; diabetes; clinical metabolic research
Dr. Roberta D'Assante

E-Mail Website
Guest Editor
Department of Translational Medical Sciences, “Federico II” University Hospital and School of Medicine, Naples, Italy
Interests: cardiovascular endocrinology; heart failure; biomarkers

Special Issue Information

Dear Colleagues,

The growing prevalence of cardiometabolic diseases is gaining increasing attention in the clinical and pharmaceutical arena. The latest advances in scientific research have made it possible to develop novel clinical tools and improve primary prevention and treatment in order to reduce cardiovascular risk. Against this challenging landscape, a great deal of work still needs to be done.

A step in the right direction has been taken by shedding new light on the wide range of cardiovascular and endocrine alterations that contribute to the impact on the pathophysiology and prognosis of patients affected with this multifactorial disease.

This could be achieved through the identification of new common pathways within various cardiometabolic diseases, and new biomarkers that can help with diagnosis, prognosis, and treatment.

The aim of the current Special Issue is to provide a holistic and multidisciplinary view of the different aspects of cardiometabolic diseases, and to identify a common approach to improve patient care and life expectancy.

Manuscripts from different research areas, ranging from basic to clinical research, are highly desired.

Prof. Dr. Antonio Cittadini
Dr. Roberta D'Assante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic disease
  • metabolism
  • cardiovascular disease
  • cardiovascular risk
  • endocrinology
  • biomarkers
  • diabetes

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

get_app
Article
Metabolic Signatures Elucidate the Effect of Body Mass Index on Type 2 Diabetes
by
Qiuling Dong
,
Sidra Sidra
,
Christian Gieger
,
Rui Wang-Sattler
,
Wolfgang Rathmann
,
Cornelia Prehn
,
Jerzy Adamski
,
Wolfgang Koenig
,
Annette Peters
,
Harald Grallert
and
Sapna Sharma
Metabolites 2023, 13(2), 227; https://doi.org/10.3390/metabo13020227 - 03 Feb 2023
Viewed by 569
Abstract
Obesity plays an important role in the development of insulin resistance and diabetes, but the molecular mechanism that links obesity and diabetes is still not completely understood. Here, we used 146 targeted metabolomic profiles from the German KORA FF4 cohort consisting of 1715 [...] Read more.
Obesity plays an important role in the development of insulin resistance and diabetes, but the molecular mechanism that links obesity and diabetes is still not completely understood. Here, we used 146 targeted metabolomic profiles from the German KORA FF4 cohort consisting of 1715 participants and associated them with obesity and type 2 diabetes. In the basic model, 83 and 51 metabolites were significantly associated with body mass index (BMI) and T2D, respectively. Those metabolites are branched-chain amino acids, acylcarnitines, lysophospholipids, or phosphatidylcholines. In the full model, 42 and 3 metabolites were significantly associated with BMI and T2D, respectively, and replicate findings in the previous studies. Sobel mediation testing suggests that the effect of BMI on T2D might be mediated via lipids such as sphingomyelin (SM) C16:1, SM C18:1 and diacylphosphatidylcholine (PC aa) C38:3. Moreover, mendelian randomization suggests a causal relationship that BMI causes the change of SM C16:1 and PC aa C38:3, and the change of SM C16:1, SM C18:1, and PC aa C38:3 contribute to T2D incident. Biological pathway analysis in combination with genetics and mice experiments indicate that downregulation of sphingolipid or upregulation of phosphatidylcholine metabolism is a causal factor in early-stage T2D pathophysiology. Our findings indicate that metabolites like SM C16:1, SM C18:1, and PC aa C38:3 mediate the effect of BMI on T2D and elucidate their role in obesity related T2D pathologies. Full article
(This article belongs to the Special Issue Advances in Cardiometabolic Research)
►▼ Show Figures

Graphical abstract

get_app
Article
The Importance of HDL-Cholesterol and Fat-Free Percentage as Protective Markers in Risk Factor Hierarchy for Patients with Metabolic Syndrome
by
Ivona Mitu
,
Cristina-Daniela Dimitriu
,
Cristina Preda
,
Ovidiu Mitu
,
Irina-Iuliana Costache
,
Radu-Ștefan Miftode
and
Manuela Ciocoiu
Metabolites 2022, 12(12), 1217; https://doi.org/10.3390/metabo12121217 - 04 Dec 2022
Cited by 1 | Viewed by 568
Abstract
This research focused on establishing a hierarchy concerning the influence of various biological markers and body composition parameters on preventing, diagnosing and managing Metabolic Syndrome (MetS). Our cross-sectional cohort study included 104 subjects without any atherosclerotic antecedent pathology, organized in two groups (with [...] Read more.
This research focused on establishing a hierarchy concerning the influence of various biological markers and body composition parameters on preventing, diagnosing and managing Metabolic Syndrome (MetS). Our cross-sectional cohort study included 104 subjects without any atherosclerotic antecedent pathology, organized in two groups (with and without MetS). All participants underwent clinical and anthropometric measurements, DEXA investigation and blood tests for all MetS criteria, together with adiponectin, leptin, insulin, uric acid and CRP. Based on mathematical logic, we calculated a normalized sensitivity score to compare the predictive power of biomarkers and parameters associated with MetS, upon the prevalence of MetS. Patients with MetS report higher levels of uric acid (p = 0.02), CRP (p = 0.012) and lower levels of adiponectin (p = 0.025) than patients without MetS. The top three biological markers with the highest predictive power of the prevalence of the disease are HDL, insulin, and adiponectin:leptin ratio, and the top three body composition parameters are trunk fat-free percentage, waist-height ratio and trunk fat percentage. Their high sensitivity scores differentiate them from all the other markers analysed in the study. Our findings report relevant scores for estimating the importance of cardiometabolic risks in the prevalence of MetS. The high rank of protective markers, HDL and trunk fat-free percentage, suggest that positive effects have a stronger association with the prevalence of MetS, than negative ones do. Therefore, this risk stratification study provides important support for prevention and management programs regarding MetS. Full article
(This article belongs to the Special Issue Advances in Cardiometabolic Research)
►▼ Show Figures

Figure 1

Other

Jump to: Research

get_app
Systematic Review
Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review
by
Francesco Nappi
and
Sanjeet Singh Avtaar Singh
Metabolites 2023, 13(3), 430; https://doi.org/10.3390/metabo13030430 - 16 Mar 2023
Viewed by 297
Abstract
Endothelial integrity plays a major role in homeostasis and is responsive to the numerous endogenous factors released. While its functional role in vascular tone is well described, its role in the pathophysiology of cardiovascular disease is of interest as a potential therapeutic target. [...] Read more.
Endothelial integrity plays a major role in homeostasis and is responsive to the numerous endogenous factors released. While its functional role in vascular tone is well described, its role in the pathophysiology of cardiovascular disease is of interest as a potential therapeutic target. We performed a systematic review to provide an overview of new therapeutic and diagnostic targets for the treatment of coronary artery disease related to endothelial dysfunction. Databases of PubMed, Ovid’s version of MEDLINE, and EMBASE were interrogated with appropriate search terms. Inclusion criteria have been met by 28 studies that were included in the final systematic review. We identified inflammation, pulmonary hypertension, diabetes mellitus and Fabry disease as pathophysiological mechanisms and explored the therapeutic options related to these conditions including medications such as Canakinumab. Endothelial dysfunction has a key role in several different pathophysiological processes which can be targeted for therapeutic options. Ongoing research should be targeted at making the transition to clinical practice. Further research is also needed on understanding the amelioration of endothelial dysfunction with the use of cardiovascular medications. Full article
(This article belongs to the Special Issue Advances in Cardiometabolic Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop